Three clinical-stage biopharmaceutical companies moved to go public this week, filing amended S-1 registration statements with the Securities and Exchange Commission covering a cardiovascular drug, an immune-disease biologics platform, and a metabolic disease program. Fidelity Management & Research Company has indicated non-binding interest in purchasing up to $75 million in shares as a cornerstone investor. Braveheart is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. Attovia is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its Attobody biologics platform, in-licensed from Alamar Biosciences.2 The platform uses an evolution-driven, high-throughput process to discover biparatopic and multispecific biologics. Vogenx estimates net proceeds of approximately $67.8 million based on an assumed offering price of $12.00 per share.3Vogenx is a clinical-stage biopharmaceutical company focused on disorders linked to human metabolism, including post-bariatric hypoglycemia and gastroparesis.